IP Library Granted Patent US 9,801,948
Granted Patent B2
US 9,801,948 · App. 14/343,809 · Granted Oct 31, 2017

Antimicrobial compositions and methods of use thereof

Inventors: Sidney Altman (Hamden, CT); Alfred Bothwell (Guilford, CT); Choukri Mamoum (Farmington, CT)
Assignee: Yale University
A61K47/48246A61K47/48092C12Q1/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,801,948
App. No.
14/343,809
Granted
Oct 31, 2017
Kind
B2
Abstract

Antimicrobial compositions including a cell penetrating peptide (CPP) having the amino acid sequence Tyr-Ala-Arg-Val-Arg-Arg-Arg-Gly-Pro-Arg-Gly-Tyr-Ala-Arg-Val-Arg-Arg-Arg-Gly-Pro-Arg-Arg (SEQ ID NO:1) or variant thereof are disclosed. The CPP, which itself has antimicrobial properties, can be advantageously combined with or conjugated to a cargo to increase the delivery, efficacy, or combinations thereof, of the cargo into cells. In preferred embodiments, the CPP is combined with or conjugated to a functional nucleic acid, such as an external guide sequence (EGS) which can target and reduce expression of essential microbial genes or genes than impart resistance to antimicrobial drugs. Methods of using the compositions alone or in combination with traditional antimicrobial drugs to treat infections are also disclosed.

Claims (16)

1. A composition comprising

a basic cell penetrating peptide (CPP) comprising the amino acid sequence of SEQ ID NO:1 or a variant of SEQ ID NO:1 having at least 90% sequence identity to SEQ ID NO:1,

and an external guide sequence (EGS).

2. The composition of claim 1 wherein the EGS is conjugated to the CPP.

3. The composition of claim 2 wherein the EGS is covalently conjugated to the CPP.

4. The composition of claim 1 wherein the EGS comprises a sequence antisense to a target mRNA.

5. The composition of claim 4 wherein the target mRNA is encoded by an essential microbial gene or antimicrobial resistance gene.

6. The composition of claim 4 wherein the target mRNA is encoded by a gene comprising the nucleic acid sequence SEQ ID NO: 4, 5, 6, 7, 8, 9, 12, 15, 16, 17, 18, or 19.

7. The composition of claim 1 wherein the EGS comprises the nucleic acid sequence SEQ ID NO: 14, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, or 37.

8. The composition of claim 1 wherein the EGS is a morpholino oligonucleotide.

9. The composition of claim 1 wherein the composition further comprises an antimicrobial drug.

10. The composition of claim 1 wherein the CPP is not a fusion partner in a fusion protein.

11. The composition of claim 1 wherein the CPP comprises the amino acid sequence of SEQ ID NO: 1, 2, 3, 49, 50, 51, 52, or 53.

12. The composition of claim 1 , wherein the CPP is conjugated to the EGS, and wherein the EGS comprises a sequence comprising five nucleotides of complementarity to an mRNA encoding an essential microbial gene or antimicrobial resistance gene.

13. The composition of claim 12 , wherein the CPP-EGS conjugate binds more tightly to the mRNA relative to an unconjugated EGS having the same sequence.

14. The composition of claim 12 , wherein the CPP comprises the amino acid sequence of SEQ ID NO:1.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jun 8, 2016
From: YALE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 038914/0135 →
Continuity (3)
Provisional Application 61537326 · Sep 21, 2011
Provisional Application 61590062 · Jan 24, 2012
Related Publication 20140220086A1 · Aug 7, 2014